32924 Sustained treatment effect of spesolimab over 12 weeks for generalized pustular psoriasis flares; results from the Effisayil 1 study

Generalized pustular psoriasis (GPP) is a rare, life-threatening autoinflammatory disease. In Effisayil 1 (NCT03782792), a double-blind, randomized, placebo-controlled study in patients presenting with a GPP flare, spesolimab, an anti-interleukin 36 receptor antibody, led to rapid clearance (within 1 week) of pustular and skin lesions. Here, we explore the effects of spesolimab over the 12-week study duration, based on observed case analysis. Patients (N = 53) were randomized to receive a single intravenous dose of spesolimab 900 mg (n = 35) or placebo (n = 18) on Day 1.